In this AJMC® roundtable discussion, oncology health care decision-making experts consider factors that affect the use of cancer immunotherapies (CITs) and discuss approaches for actualizing policies and procedures within community oncology teams.
Evaluating the Management of Cancer Immunotherapy (CIT): Roundtable Discussion
Advertisement
Advertisement
Trending on AJMC
1
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
2
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
3
New Partnership Model Boosts Maternal Outcomes in Medicaid ACOs
4
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
5
